ClinicalTrials.gg
CompletedNCT05901311Updated Nov 8, 2024

A Study of [14C]-LY3537982 in Healthy Participants

A Phase 1 interventional study of LY3537982 and [¹⁴C]-LY3537982 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants in good health, determined by no findings from medical history, physical examination as assessed by the investigator.
  • Have a within the range 18.5 to 32.0 kilograms per meter squared (kg/m²)
  • Female participants of non- and male participants who follow standard methods.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    [¹⁴C]-LY3537982 (Part 1)

    Single dose of \[¹⁴C\]-LY3537982 administered orally.

    Drug: [¹⁴C]-LY3537982

  • Experimental
    [¹⁴C]-LY3537982 + LY3537982 (Part 2)

    Single dose of LY3537982 administered orally followed by \[¹⁴C\]-LY3537982 administered intravenously (IV).

    Drug: LY3537982 · Drug: [¹⁴C]-LY3537982

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Fraction of Dose Excreted in Urine (Feur)

    PK: Feur

    Time frame: Predose on day 1 up to postdose on day 21 (Part 1)

  2. PK: Cumulative Feur

    PK: Cumulative Feur

    Time frame: Predose on day 1 up to postdose on day 21 (Part 1)

  3. PK: Fraction of Dose Excreted in Feces (Fefeces)

    PK: Fefeces

    Time frame: Predose on day 1 up to postdose on day 21 (Part 1)

  4. PK: Cumulative Fefeces

    PK: Cumulative Fefeces

    Time frame: Predose on day 1 up to postdose on day 21 (Part 1)

  5. PK: Fraction of Dose Excreted in Expired Air (Feair)

    PK: Feair

    Time frame: Predose on day 1 up to postdose on day 21 (Part 1)

  6. PK: Absolute Bioavailability (F) of LY3537982

    PK: F of LY3537982

    Time frame: Predose on day 1 up to postdose on day 9 (Part 2)

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2023
First posted
Jun 13, 2023
StartActual
Jun 5, 2023
Primary completionActual
Aug 10, 2023
CompletionActual
Aug 10, 2023
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05901311
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Jun 5, 2023
Primary completion
Aug 10, 2023
Completion
Aug 10, 2023
Last update
Nov 8, 2024

Study contacts

Yingying Guo-Avrutin, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olomorasib

Start the discussion